Post-marketing clinical safety evaluation of Zedoary Turmeric Oil Injection and centralized monitoring in hospitals

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064482

Enrollment

Unknown

Registered

2022-10-09

Start date

2022-09-30

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory, Digestive, Pediatric, Infectious Diseases

Interventions

Experimental group:Zedoary Turmeric Oil Injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who meet the instructions for Zedoary Turmeric Oil Injection or clinicians judge that they are suitable for applying Zedoary Turmeric Oil Injection according to the patient's condition. 2. Voluntarily or with the consent of the guardian to participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those who are known to have a history of allergy to Zedoary Turmeric Oil Injection. 2. Those who have a known history of allergy to Twain 80. 3. The researcher judges that it is impossible to complete or is not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame
Adverse Drug Reaction;Adverse Drug Event;	—

Countries

China

Contacts

Public ContactBan Chengjun, Tian Guihua, Shang Hongcai

Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine

shanghongcai@foxmail.com+86 18202525733

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026